Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
During the Academy of Managed Care Pharmacy (AMCP) annual meeting, Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighed in on the factors he thinks will most impact market share among adalimumab biosimilars when they enter the US market in 2023
Transcript
With there being 7 FDA-approved adalimumab biosimilars and potentially more coming in the next year and a half, what factor do you think is going to be the most impactful on market share?
There's 7 that could be launched because they're approved currently, but there's actually 8, so we could get 8 original formulations in 2023. In 2023, we could get a couple 100-mg/mL approvals. So, I would say in 2023, the highest potential number we could get is around 10 launches.
And then the most impactful factors on their adoption: No. 1 is that about 2 or 3 weeks ago, there was a settlement agreement between Alvotech and AbbVie. And this had to do with the new formulation [100 mg/mL, high concentration]. It was very unclear, very cloudy on the future of biosimilars to the new formulation of Humira [reference adalimumab] coming to market and when that would take place. The settlement agreement kind of cleared that up; the skies got nice and blue. And we think that now we're going to get that 100-mg/mL launch in mid 2023. So, that's by far the most impactful thing because 80% of the utilization or more for Humira is in that new formulation.
So, that changes the view from a payer standpoint on how to add those products to the formulary. Citrate free is a is another issue that we'll mention that's impactful. One thing maybe people aren't thinking about is AbbVie's willingness to contract Humira cost down. So that will impact the adoption of biosimilar. How low are they willing to go? Interchangeability, the ever-elusive interchangeability, will also impact that.
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.